CN117737210A - Method for detecting proportion of mRNA with poly A tail in mRNA product - Google Patents
Method for detecting proportion of mRNA with poly A tail in mRNA product Download PDFInfo
- Publication number
- CN117737210A CN117737210A CN202211106161.XA CN202211106161A CN117737210A CN 117737210 A CN117737210 A CN 117737210A CN 202211106161 A CN202211106161 A CN 202211106161A CN 117737210 A CN117737210 A CN 117737210A
- Authority
- CN
- China
- Prior art keywords
- mrna
- cdna
- sequence
- digital pcr
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000007847 digital PCR Methods 0.000 claims abstract description 33
- 239000000523 sample Substances 0.000 claims abstract description 32
- 239000002299 complementary DNA Substances 0.000 claims abstract description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 14
- 238000010839 reverse transcription Methods 0.000 claims abstract description 10
- 230000004048 modification Effects 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 4
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 230000026731 phosphorylation Effects 0.000 claims description 3
- 238000006366 phosphorylation reaction Methods 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 2
- 238000012257 pre-denaturation Methods 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 125000006853 reporter group Chemical group 0.000 claims description 2
- 238000013461 design Methods 0.000 abstract description 4
- 238000003908 quality control method Methods 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 18
- 239000012634 fragment Substances 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710086015 RNA ligase Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- AGWRKMKSPDCRHI-UHFFFAOYSA-K [[5-(2-amino-7-methyl-6-oxo-1H-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-5-(6-aminopurin-9-yl)-4-methoxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound COC1C(OP([O-])(=O)OCC2OC(C(O)C2O)N2C=NC3=C2N=C(N)NC3=O)C(COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OCC2OC(C(O)C2O)N2C=[N+](C)C3=C2N=C(N)NC3=O)OC1N1C=NC2=C1N=CN=C2N AGWRKMKSPDCRHI-UHFFFAOYSA-K 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002055 nanoplate Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229940126582 mRNA vaccine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- -1 specifically Proteins 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
Abstract
The present invention provides a method for detecting the proportion of mRNA having a polyA tail in an mRNA product. The method of the invention comprises the following steps: 1) Obtaining RNA with a connector at the 3' end; 2) Performing reverse transcription to obtain cDNA; 3) Designing synthetic primers and probes for the 5 'end of the cDNA, designing synthetic primers and probes for the 3' end of the cDNA, and preparing a digital PCR reaction system for determination. The invention designs a corresponding primer and a probe according to the requirement of mRNA product quality control, and provides a method for effectively, stably and accurately detecting the proportion of mRNA with poly A tail in an mRNA product by matching with a digital PCR method.
Description
Technical Field
The invention relates to a method for detecting the proportion of mRNA with poly A tail in mRNA product, which can be applied in the fields of quality control of mRNA product and the like.
Background
The market of two mRNA vaccines in 2020 announces that mRNA technology formally enters the commercial era, and mRNA also enters the rapid development stage. mRNA is used as the technical basis of medicines and vaccines, and has great flexibility in production and application. Any protein can be encoded and expressed by mRNA and in principle prophylactic and therapeutic vaccines can be developed against various diseases, such as infections and cancers, as well as protein replacement therapies.
The preparation process of the mRNA product can be roughly divided into three stages: 1) Preparing linear DNA, wherein the stage mainly comprises constructing a vector containing a target gene, carrying out plasmid amplification by engineering bacteria and linearizing the DNA; 2) Preparing mRNA stock solution, wherein the mRNA is prepared mainly by taking linear DNA of the previous stage as a template by an in vitro transcription technology, and the prepared mRNA structure comprises a 5 '-end capping structure and a 3' -end poly A tailing structure; 3) The liposome is encapsulated, mRNA and nano delivery materials are self-assembled to form nano ions by adopting different technologies at the stage, and the nano ions are filled after concentration, purification and sterile filtration. The 3 '-terminal poly A is a non-templated adenosine added at the 3' -end of the mRNA molecular structure, and plays a key role in translation and stability of mRNA. It is therefore necessary to detect the proportion of intact mRNA having a polyA tail to ensure the quality of the mRNA product.
There are two main methods for detecting nucleic acids in common use at present: the real-time quantitative PCR detection method and the digital PCR detection method have higher accuracy in quantitatively detecting the copy number, and are more convenient because no standard curve is required to be designed or prepared. The current digital PCR technology uses micro-chamber/microwell or microdroplet as PCR reactor to make the template randomly distributed in microwell or microdroplet, uses high-precision camera to analyze each microwell after PCR amplification of microwell by using thermal cycler, and obtains copy number of corresponding fragment in solution by calculating number of positive microdroplet. mRNA products require detection of the proportion of mRNA having a poly A tail to ensure their translation level and stability. However, no method for stably and accurately detecting the proportion of mRNA having a poly A tail in an mRNA product has been found in the prior art.
Disclosure of Invention
The present invention provides a method for detecting the proportion of mRNA having a polyA tail in an mRNA product, comprising the steps of:
1) Obtaining RNA with a connector at the 3' end;
2) Performing reverse transcription to obtain cDNA; reverse transcription primers are designed based on the sequence of the adaptor;
3) And respectively designing a synthetic primer and a probe aiming at the 5 'end of the cDNA, respectively designing the synthetic primer and the probe aiming at the 3' end of the cDNA, and preparing a digital PCR reaction system for determination. The 5' end of the cDNA is respectively designed with a synthetic primer and a probe which are used as internal references; the 3' end of the cDNA is respectively designed with a synthetic primer and a probe for detecting a poly A tail signal. The internal reference is that in actual detection, the internal references of different RNAs to be detected need not be identical, as specified by the need. In the present invention, fragments having both 5 'and 3' signals are defined as complete sequences in the assay. The invention also allows detection of the proportion of RNA containing incomplete poly A by targeted design of the primers. The length of poly A of the RNA to be detected is not limited in the present invention.
Preferably, the method further comprises calculating the proportion of mRNA having poly a tails based on the copy number of the digital PCR assay. Preferably, the proportion of mRNA with poly a tail is: at the same time, the copy number of the signals of the poly A and the reference gene/the copy number of the reference gene is multiplied by 100 percent.
According to a specific embodiment of the present invention, wherein the method further comprises a process of ligating mRNA with a linker to obtain the RNA having the linker at the 3' end;
preferably, the molar ratio of mRNA to linker is 1:5-20.
According to a specific embodiment of the present invention, wherein the method further comprises purifying, and the RNA having a linker at the 3' end is the purified RNA.
According to a specific embodiment of the present invention, wherein the step of reverse transcribing the RNA molecule further comprises reverse transcribing the purified mRNA with specific primers.
According to a specific embodiment of the present invention, the step of preparing a digital PCR reaction system further comprises subjecting the cDNA to purity and concentration analysis followed by appropriate dilution.
According to a specific embodiment of the present invention, the 5' end of the linker has one or more phosphorylation modifications;
preferably, the 3' end of the linker carries one or more ddC markers. The 5 'phosphorylation modification allows the linker to be attached to the 3' end of the mRNA, and the 3'ddC tag ensures that the mRNA will not be attached to the 3' end of the linker.
According to a specific embodiment of the present invention, wherein the probe is modified with a fluorophore, the modification comprising:
the 5 '-end base of the probe is modified by adopting a fluorescent reporter group, and the 3' -end base of the probe is modified by adopting a fluorescent quenching group.
According to a specific embodiment of the present invention, the sequence of the forward primer designed for the 5' end of the cDNA is: 5'-TGTTTGTGTTCCTGGTGCTG-3' (SEQ ID NO. 1);
preferably, the sequence of the reverse primer designed for the 5' end of the cDNA is: 5'-CGGAGCTCCTGAACACCTTA-3' (SEQ ID NO. 2);
preferably, the sequence of the probe designed for the 5' end of the cDNA is: 5 'ACTCCTCACCCCGGGCGTGT-3' (SEQ ID NO. 3);
preferably, the forward primer designed for the 3' end of the cDNA has the sequence: 5'-CTTGCCTTCTGGCCATGC-3' (SEQ ID NO. 4);
preferably, the sequence of the reverse primer designed for the 3' end of the cDNA is: 5'-AGTCATATGCTTTTTTTTTT-3' (SEQ ID NO. 5);
preferably, the sequence of the probe designed for the 3' end of the cDNA is: 5'-CCTTGCACCTGTACCTCTTGGTCTTT-3' (SEQ ID NO. 6).
According to a specific embodiment of the present invention, wherein the 5 'end of the probe designed for the 5' end of the cDNA is modified with VIC; the 3 'end of the probe designed for the 5' end of the cDNA is modified by BHQ-1;
preferably, the 5 'end of the probe designed for the 3' end of the cDNA is provided with FAM modification; the 3 'end of the probe designed for the 3' end of the cDNA is provided with BHQ-1 modification.
According to a specific embodiment of the present invention, wherein the sequence of the linker comprises the sequence shown in SEQ ID NO.7: SEQ ID NO.7:5'-TCGTATGCCGTCTTCTGCTTG-3'.
According to a specific embodiment of the present invention, wherein the sequence of the reverse transcribed primer comprises the sequence shown as SEQ ID NO.8, SEQ ID NO.8:5'-AGCAGAAGACGGCATACGA-3'.
According to a specific embodiment of the present invention, wherein the digital PCR is a titration type digital PCR;
preferably, the digital PCR is a dual probe digital PCR.
According to a specific embodiment of the present invention, the ligation reaction is performed as follows:
the mRNA product is denatured for 10 minutes at 60-80 ℃ and then rapidly placed on ice for cooling;
the prepared ligation system was incubated at 25℃for 2-6 hours.
According to a specific embodiment of the present invention, the digital PCR reaction step comprises:
1) Pre-denaturation at 95℃for 2-5 min, 1 cycle;
2) Denaturation at 95℃for 5-60 seconds, annealing at 50℃for 5-60 seconds, elongation at 72℃for 5-120 seconds, and a total of 30-40 cycles.
The invention also provides a kit for detecting the proportion of mRNA having a polyA tail in an mRNA product, wherein the kit comprises:
a linker comprising the sequence shown as SEQ ID NO.7 and/or a reverse transcription primer comprising the sequence shown as SEQ ID NO. 8.
The invention has the beneficial effects that:
the invention designs a corresponding primer and a probe according to the requirement of mRNA product quality control, and provides a method for effectively, stably and accurately detecting the proportion of mRNA with poly A tail in an mRNA product by matching with a digital PCR method.
The invention analyzes the sequence characteristics of the produced mRNA according to the requirement of mRNA product quality control, and designs a primer, a probe, a method and a PCR program which are applicable to detecting the proportion of complete mRNA containing poly A tail in the mRNA product with similar sequence. The digital PCR technology is matched with the primer and the probe to accurately quantify the proportion of the complete mRNA with the polyA tail in the mRNA product, thereby providing guarantee for the effectiveness and the safety of the mRNA product.
Drawings
FIG. 1 is a schematic diagram of the steps for detecting mRNA tailing rate by digital PCR.
FIG. 2 is data from the detection of mRNA tail-rate space-time white wells using digital PCR, where green represents the copy number of poly A and yellow represents the copy number of the reference fragment.
FIG. 3 shows the result of digital PCR of mRNA after ligation and reverse transcription after the addition of the tail rate of mRNA by digital PCR, wherein green represents the copy number of poly A and yellow represents the copy number of the reference fragment.
Detailed Description
The technical solution of the present invention will be described in detail below for a clearer understanding of technical features, objects and advantageous effects of the present invention, but should not be construed as limiting the scope of the present invention.
Instrument and equipment
PCR instrument, desk centrifuge, digital PCR instrument, nanodrop ultra-micro spectrophotometer, vortex suspension, ultra-clean bench, etc.
Reagent(s)
Primers and probes (organisms) (SEQ ID NO. 1-SEQ ID NO. 6), adaptors (Suzhou Bei Xin) (SEQ ID NO. 7), T4 RNA library 1 (NEB), QIAcuity TM Probe PCR Kit Kit (Qiagen), MEGAclear Transcription Clean-Up Kit (Invitrogen).
The sequences of the mRNAs involved in the examples are as follows:
the cap structure is as follows: in the present invention, the cap structures used are m7G (5 ') ppp (5') (2 'OMeA) pG, m7G (5') ppp (5 ') (2' OMeA), G (5 ') ppp (5') G, m G (5 ') ppp (5') G, 3'-O-Me-m7G (5') ppp (5 ') G or m7 (3' OMeG) (5 ') ppp (5') (2 'OMeA) pG, preferably m7G (5') ppp (5 ') (2' OMeA) pG.
"T" is used in the present invention to represent uracil (U) in RNA, specifically, mRNA sequence:
examples
This example provides a method for detecting the proportion of mRNA having a polyA tail in an mRNA product. The schematic of the steps for detecting mRNA tailing rate by digital PCR is shown in FIG. 1.
The method comprises the following specific steps:
1. obtaining RNA with a linker at the 3' end:
(1) Ligation reaction
1) The mRNA was heat denatured at 65℃for 10 minutes and then placed on ice for rapid cooling;
2) A20. Mu.l ligation reaction was established:
1×T4 RNA Ligase Reaction Buffer(50mM Tris-HCl,pH 7.5,10mM MgCl 2 ,1mM DTT)
15~25%(wt/vol)PEG 8000
10%(v/v)DMSO
0.5μl RNase inhibitor(40U/μl)
1mM ATP
20pmol RNA product
40~200pmol RNA adaptor
1μl(10units)T4 RNA ligase;
3) After incubation at 25℃for 4 hours, thermal denaturation at 65℃for 10 minutes.
(2) And (3) RNA separation and purification:
1) The samples subjected to the ligation reaction were filled up to 100. Mu.l with an Elutation Buffer, and gently mixed with a pipette tip;
2) Adding 350 μl Binding Buffer, and gently mixing with a suction head;
3) 250 μl of 100% ethanol was added and gently mixed with a suction head;
4) Inserting an RNA micro adsorption column into a collecting pipe, lightly mixing the sample obtained in the step 3) by using a suction head, transferring the mixture onto the RNA micro adsorption column, centrifuging at room temperature of 14000g for 1 minute, and discarding the filtrate, wherein the total volume of the mixture is not more than 700 mu l at a time (each adsorption column can bear 500 mu g mRNA at most);
5) Repeating the steps 3) -4) until all the samples are transferred to a micro adsorption column;
6) 550 μl of Washing Buffer was added;
7) Centrifuging 14000g for 1 min at room temperature, and discarding the filtrate;
8) Repeating steps 6) -7);
9) Centrifuging 14000g of the empty RNA micro adsorption column for 2 minutes at room temperature to dry column matrix;
10 Transferring the RNA micro adsorption column into a new collecting pipe, uncovering and standing for 2-3 minutes;
11 100 mu l RNase Free Water, and standing for 10 minutes;
12 14000g for 2 minutes at room temperature;
13 The micro adsorption column is discarded, the dissolved mRNA is transferred to a new 1.5ml centrifuge tube, fully mixed and marked, and a proper amount of mRNA is taken out for cDNA preparation.
2. Obtaining cDNA:
first, a reverse transcription reaction system was prepared as shown in Table 1.
TABLE 1
Buffer | Volume (mul) |
5×Prime Script Buffer | 1 |
Prime Script RT Enzyme MixⅠ | 0.25 |
Primer (SEQ ID NO. 8) | 0.25 |
RNase Free dH 2 O | 2.5 |
cDNA template | 1 |
The prepared reaction system was subjected to reverse transcription according to the procedure shown in Table 2.
TABLE 2
And after the reverse transcription is finished, the PCR tube is taken out from the PCR instrument, and a proper amount of sterile deionized water is added for purity and concentration analysis and then used for subsequent digital PCR detection.
3. Digital PCR reaction:
1) DPCR reaction mixtures were prepared according to table 3.
TABLE 3 Table 3
2) Vortex mixing for 30 seconds;
3) Transferring the content of each well from a standard PCR tube into a nanopore well;
4) The nano-plate sealing film is used for correctly sealing the nano-plate;
5) The digital PCR reactions were performed as follows:
step 1:95 ℃ for 2 minutes
Step 2:95 ℃ for 15 seconds
Step 3:50 ℃ for 10 seconds
Step 4:72 ℃ for 15 seconds
Step 2 through Step 4 were performed for 39 cycles.
The digital PCR fluorescent signal acquisition results are shown in FIG. 2 and FIG. 3.
As can be seen from FIG. 2, when the blank wells were detected by digital PCR, only (-) positive droplets (aerosol contamination) were observed in the fluorescent droplets, i.e., only the reference fragment sequence and (-) positive droplets (aerosol contamination) were detected, i.e., only the Poly-A tail sequence, whereas (++) double positive droplets were almost zero, i.e., both the reference fragment sequence and the Poly-A tail sequence, and the primers and probes for detecting the reference fragment sequence and the Poly-A tail sequence were not interfered with. The detection accuracy is good.
As can be seen from FIG. 3, standard plasmids with complete reference sequence and Poly-A tail sequence were tested by digital PCR and were seen in fluorescent droplets: the proportion of positive droplets (- +) that is, only the reference fragment sequence and (-) that is, only the Poly-A tail sequence are detected is very small and the proportion of double positive droplets (++) that are the existing reference fragment sequence and Poly-A tail sequence to positive droplets is 94.6%, indicating that digital PCR is effective in detecting RNA having both the reference sequence and the Poly-A sequence.
4. Calculating the proportion of mRNA having a poly A tail
Copy number calculation from digital PCR assay: proportion of mRNA with polya tail = copy number of signal with both polya and reference gene/reference gene copy number. As can be seen from FIG. 3, the proportion of mRNA having a poly A tail in this example was 97.3% (97.3% = 13519/(369+13519). Times.100%).
The embodiments described above may be modified in various ways by those skilled in the art without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and not by the foregoing detailed description, and each implementation within the scope of which is defined by the present invention.
Claims (11)
1. A method of detecting the proportion of mRNA having a poly a tail in an mRNA product, the method comprising:
1) Obtaining RNA with a connector at the 3' end;
2) Performing reverse transcription to obtain cDNA;
3) Designing synthetic primers and probes for the 5 'end of the cDNA, designing synthetic primers and probes for the 3' end of the cDNA, and preparing a digital PCR reaction system for determination.
2. The method of claim 1, wherein the method further comprises calculating the proportion of mRNA having poly a tails based on the copy number of the digital PCR assay.
3. The method of claim 1 or 2, wherein the method further comprises the step of ligating mRNA with a linker to obtain the 3' -end-ligated RNA.
4. A method according to any one of claims 1 to 3 wherein the 5' end of the linker carries one or more phosphorylation modifications; preferably, the 3' end of the linker carries one or more ddC markers.
5. The method of any one of claims 1-4, wherein the probe is modified with a fluorophore, the modification comprising:
the base at the 5 '-end of the probe sequence is modified by adopting a fluorescent reporter group, and the base at the 3' -end of the probe sequence is modified by adopting a fluorescent quenching group.
6. The method of any one of claims 1-5, wherein the 5 'end of the probe designed for the 5' end of the cDNA has a VIC modification; the 3 'end of the probe designed for the 5' end of the cDNA is modified by BHQ-1;
the 5 'end of the probe designed for the 3' end of the cDNA is provided with FAM modification; the 3 'end of the probe designed for the 3' end of the cDNA is provided with BHQ-1 modification.
7. The method of any one of claims 1-6, wherein the sequence of the linker comprises the sequence set forth in SEQ ID No.7, SEQ ID No.7:5'-TCGTATGCCGTCTTCTGCTTG-3'.
8. The method of any one of claims 1-7, wherein the sequence of the reverse transcribed primer comprises the sequence set forth in SEQ ID No.8, SEQ ID No.8:5'-AGCAGAAGACGGCATACGA-3'.
9. The method of any one of claims 1-8, wherein the digital PCR is a titrated digital PCR.
10. The method of any one of claims 1-9, wherein the digital PCR reaction step comprises:
1) Pre-denaturation at 95℃for 2-5 min;
2) Denaturation at 95℃for 5-60 seconds, annealing at 50℃for 5-60 seconds and elongation at 72℃for 5-120 seconds.
11. A kit for detecting the proportion of mRNA having a poly a tail in an mRNA product, the kit comprising:
a linker comprising the sequence shown as SEQ ID NO.7 and/or a reverse transcription primer comprising the sequence shown as SEQ ID NO. 8.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211106161.XA CN117737210A (en) | 2022-09-09 | 2022-09-09 | Method for detecting proportion of mRNA with poly A tail in mRNA product |
PCT/CN2023/117779 WO2024051832A1 (en) | 2022-09-09 | 2023-09-08 | Method for detecting proportion of mrna with polya tail in mrna product |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211106161.XA CN117737210A (en) | 2022-09-09 | 2022-09-09 | Method for detecting proportion of mRNA with poly A tail in mRNA product |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117737210A true CN117737210A (en) | 2024-03-22 |
Family
ID=90192090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211106161.XA Pending CN117737210A (en) | 2022-09-09 | 2022-09-09 | Method for detecting proportion of mRNA with poly A tail in mRNA product |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117737210A (en) |
WO (1) | WO2024051832A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2198293B1 (en) * | 2007-09-07 | 2012-01-18 | Fluidigm Corporation | Copy number variation determination, methods and systems |
CN102277351A (en) * | 2010-06-10 | 2011-12-14 | 中国科学院上海生命科学研究院 | Method for acquiring gene information and function genes from species without genome referenced sequences |
EP3724355A1 (en) * | 2017-12-15 | 2020-10-21 | Novartis AG | Polya tail length analysis of rna by mass spectrometry |
-
2022
- 2022-09-09 CN CN202211106161.XA patent/CN117737210A/en active Pending
-
2023
- 2023-09-08 WO PCT/CN2023/117779 patent/WO2024051832A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024051832A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210355537A1 (en) | Compositions and methods for identification of a duplicate sequencing read | |
US10995367B2 (en) | Vesicular adaptor and uses thereof in nucleic acid library construction and sequencing | |
CN109468384B (en) | Composite amplification detection kit for simultaneously detecting 45Y loci | |
US8574864B2 (en) | Methods and kits for 3'-end-tagging of RNA | |
EP3152316B1 (en) | Sample preparation for nucleic acid amplification | |
US20150105299A1 (en) | Method for Differentiation of Polynucleotide Strands | |
JP2010516284A (en) | Methods, compositions and kits for detection of microRNA | |
EP3192901A1 (en) | Method for constructing nucleic acid single-stranded cyclic library and reagents thereof | |
US11761037B1 (en) | Probe and method of enriching target region applicable to high-throughput sequencing using the same | |
CA2905410A1 (en) | Systems and methods for detection of genomic copy number changes | |
CN111549025B (en) | Strand displacement primer and cell transcriptome library construction method | |
CN111936635A (en) | Generation of single stranded circular DNA templates for single molecule sequencing | |
US11441169B2 (en) | Methods of small-RNA transcriptome sequencing and applications thereof | |
CN111424119B (en) | High-flux detection primer and kit for SARS-CoV-2 virus | |
ES2645418T3 (en) | Amplification of a sequence of a ribonucleic acid | |
CN117737210A (en) | Method for detecting proportion of mRNA with poly A tail in mRNA product | |
JP2018014924A (en) | PCR using helicase | |
WO2023116490A1 (en) | Novel method for detecting small rna and use thereof | |
CN114015757A (en) | Method for detecting fusion gene | |
WO2018195878A1 (en) | Dna identifier and use thereof | |
CN117822130A (en) | Library preparation method and application thereof, connector and kit | |
CN115175985A (en) | Method for extracting single-stranded DNA and RNA from untreated biological sample and sequencing | |
JP2018126078A (en) | Methods for analyzing rna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |